CO2022014598A2 - Composiciones y métodos para el direccionamiento de c9orf72 - Google Patents

Composiciones y métodos para el direccionamiento de c9orf72

Info

Publication number
CO2022014598A2
CO2022014598A2 CONC2022/0014598A CO2022014598A CO2022014598A2 CO 2022014598 A2 CO2022014598 A2 CO 2022014598A2 CO 2022014598 A CO2022014598 A CO 2022014598A CO 2022014598 A2 CO2022014598 A2 CO 2022014598A2
Authority
CO
Colombia
Prior art keywords
methods
c9orf72
addressing
compositions
systems
Prior art date
Application number
CONC2022/0014598A
Other languages
English (en)
Inventor
Benjamin Oakes
Hannah Spinner
Sarah Denny
Brett T Staahl
Kian Taylor
Katherine Baney
Isabel Colin
Maroof Adil
Cole Urnes
Sean Higgins
Original Assignee
Scribe Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scribe Therapeutics Inc filed Critical Scribe Therapeutics Inc
Publication of CO2022014598A2 publication Critical patent/CO2022014598A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

En la presente se proporcionan sistemas de Clase 2, Tipo V que comprenden nucleasas, ácidos nucleicos guía (gNA) y, opcionalmente, ácidos nucleicos de plantilla de donante útiles en la modificación de un gen C9orf72. Los sistemas también son útiles para la introducción en células, por ejemplo, células eucariotas que tienen mutaciones o duplicaciones en el gen C9orf72. También se proporcionan métodos para usar tales sistemas para modificar células que tienen tales mutaciones o duplicaciones.
CONC2022/0014598A 2020-03-18 2022-10-14 Composiciones y métodos para el direccionamiento de c9orf72 CO2022014598A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062991403P 2020-03-18 2020-03-18
PCT/US2021/022840 WO2021188729A1 (en) 2020-03-18 2021-03-17 Compositions and methods for the targeting of c9orf72

Publications (1)

Publication Number Publication Date
CO2022014598A2 true CO2022014598A2 (es) 2022-10-31

Family

ID=75478206

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0014598A CO2022014598A2 (es) 2020-03-18 2022-10-14 Composiciones y métodos para el direccionamiento de c9orf72

Country Status (11)

Country Link
EP (1) EP4121535A1 (es)
JP (1) JP2023518541A (es)
KR (1) KR20230002401A (es)
CN (1) CN116096885A (es)
AU (1) AU2021237633A1 (es)
BR (1) BR112022018673A2 (es)
CA (1) CA3172178A1 (es)
CO (1) CO2022014598A2 (es)
IL (1) IL296477A (es)
MX (1) MX2022011460A (es)
WO (1) WO2021188729A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114375334A (zh) 2019-06-07 2022-04-19 斯克里贝治疗公司 工程化CasX系统
MX2023006566A (es) * 2020-12-03 2023-08-07 Scribe Therapeutics Inc Sistemas crispr tipo v clase 2 diseñados por ingeniería.
WO2022261150A2 (en) 2021-06-09 2022-12-15 Scribe Therapeutics Inc. Particle delivery systems
WO2023077095A2 (en) * 2021-10-29 2023-05-04 Mammoth Biosciences, Inc. Effector proteins, compositions, systems, devices, kits and methods of use thereof
WO2023086389A1 (en) * 2021-11-09 2023-05-19 Prime Medicine, Inc. Genome editing compositions and methods for treatment of amyotrophic lateral sclerosis
WO2023235725A2 (en) * 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Crispr-based therapeutics for c9orf72 repeat expansion disease
WO2023240074A1 (en) 2022-06-07 2023-12-14 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
TW202405175A (zh) 2022-06-07 2024-02-01 美商斯奎柏治療公司 用於靶向pcsk9的組合物及方法
WO2023240157A2 (en) * 2022-06-08 2023-12-14 Scribe Therapeutics Inc. Compositions and methods for the targeting of dmd
WO2023240162A1 (en) * 2022-06-08 2023-12-14 Scribe Therapeutics Inc. Aav vectors for gene editing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5695937A (en) 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
US9580714B2 (en) 2010-11-24 2017-02-28 The University Of Western Australia Peptides for the specific binding of RNA targets
WO2017083722A1 (en) 2015-11-11 2017-05-18 Greenberg Kenneth P Crispr compositions and methods of using the same for gene therapy
SG11201805320XA (en) * 2015-12-23 2018-07-30 Crispr Therapeutics Ag Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
AU2017335890B2 (en) * 2016-09-30 2024-05-09 The Regents Of The University Of California RNA-guided nucleic acid modifying enzymes and methods of use thereof
WO2018195555A1 (en) 2017-04-21 2018-10-25 The Board Of Trustees Of The Leland Stanford Junior University Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors
WO2018208972A1 (en) * 2017-05-09 2018-11-15 University Of Massachusetts Methods of treating amyotrophic lateral sclerosis (als)
EP3950957A1 (en) * 2017-08-08 2022-02-09 Depixus In vitro isolation and enrichment of nucleic acids using site-specific nucleases
US11578334B2 (en) * 2017-10-25 2023-02-14 Monsanto Technology Llc Targeted endonuclease activity of the RNA-guided endonuclease CasX in eukaryotes
CN114375334A (zh) 2019-06-07 2022-04-19 斯克里贝治疗公司 工程化CasX系统

Also Published As

Publication number Publication date
CN116096885A (zh) 2023-05-09
JP2023518541A (ja) 2023-05-02
WO2021188729A1 (en) 2021-09-23
EP4121535A1 (en) 2023-01-25
AU2021237633A1 (en) 2022-10-06
KR20230002401A (ko) 2023-01-05
BR112022018673A2 (pt) 2022-12-27
MX2022011460A (es) 2022-12-15
IL296477A (en) 2022-11-01
CA3172178A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
CO2022014598A2 (es) Composiciones y métodos para el direccionamiento de c9orf72
PE20231177A1 (es) Composiciones y metodos para el direccionamiento de bcl11a referencia cruzada a solicitudes relacionadas
PE20231178A1 (es) Sistemas crispr tipo v clase 2 disenados por ingenieria
CO2018004763A2 (es) Edición genómica multiplexada
GB2572918A (en) Gene editing of PCSK9
MX2018001617A (es) Composiciones de crispr-cas9 diseñados y metodos de uso.
MX2023001088A (es) Bibliotecas de transcriptomas de celulas individuales de alto rendimiento y metodos de fabricacion y uso.
CL2019000486A1 (es) Estimuladores de sgc.
BR112016013400A2 (pt) métodos para modificar um genoma e para produzir um camundongo
CO2021006362A2 (es) Construcciones de ácido nucleico y métodos de uso
BR112015004848A2 (pt) plataforma de integração de transgene engenheirada (etip) para direcionamento de gene e empilhamento de característica
CL2019000732A1 (es) Tratamiento avv de la enfermedad de huntington.
CY1123119T1 (el) Αντινοηματικο νουκλεϊκο οξυ
CO2022013832A2 (es) Amidas heterocíclicas y su uso para modular el empalme
CO2022009248A2 (es) Anticuerpos anti-cd73 y usos de estos
CL2022002779A1 (es) Compuestos y métodos para modular el proceso de corte y empalme
BR112021013971A2 (pt) Composições e métodos para estimular células natural killer
CO2021002691A2 (es) Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1)
CL2018003649A1 (es) Edición genética mejorada
AR119887A1 (es) Agentes de unión a cd8 y sus usos
CO2017011617A2 (es) Agentes nucleósidos para la reducción de la actividad perjudicial de los genes que contienen repeticiones de nucleótidos extendidas
BR112018068601A2 (pt) método aprimorado para usar o módulo de biorreator eletroquímico com recuperação do cofator
ECSP22074446A (es) Ácidos nucleicos antisentido que inducen la omisión del exón 51
EP4349980A3 (en) Methods and compositions for the targeted modification of a genome
AR124234A1 (es) Sistemas crispr clase 2 tipo v genomodificados